Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6874

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Interventions: ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham; Drug · Other
Lead sponsor: ONL Therapeutics; Industry
Eligibility: 55 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 56
States / cities: Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 50 more

Conditions: Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
Interventions: ADX-324, Placebo; Drug
Lead sponsor: ADARx Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Litchfield Park, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 16 more

Conditions: Lung Cancer
Interventions: Standard Radiation Dose Therapy, cisplatin, etoposide, High Radiation Dose Therapy, carboplatin; Radiation · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2026
U.S. locations: 930
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 575 more

Conditions: Obesity
Interventions: CagriSema (Cagrilintide B + semaglutide I), Low Energy Diet; Drug · Behavioral
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Orlando, Florida • Baton Rouge, Louisiana

Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Anaplastic Thyroid Cancer (ATC)
Interventions: JZP815; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more

Conditions: Advanced Solid Tumor
Interventions: vilastobart (XTX101), Atezolizumab; Drug
Lead sponsor: Xilio Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 19
States / cities: Phoenix, Arizona • Duarte, California • Encinitas, California + 16 more

Conditions: Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
Interventions: Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 212
States / cities: Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more

Conditions: Metastatic Melanoma
Interventions: Cisplatin, ALT-801; Drug · Biological
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 5 more

Conditions: Ulcerative Colitis
Interventions: ABX464, Placebo; Drug
Lead sponsor: Abivax S.A.; Industry
Eligibility: 16 Years and older
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 46
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 39 more

Conditions: Ulcerative Colitis
Interventions: ABX464, Placebo; Drug
Lead sponsor: Abivax S.A.; Industry
Eligibility: 16 Years and older
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 54
States / cities: Dothan, Alabama • Guntersville, Alabama • Homewood, Alabama + 45 more

Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions: Bemarituzumab, Nivolumab, Chemotherapy, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Cerritos, California • Downey, California + 31 more

Conditions: Limb Length Discrepancy
Interventions: ultrasound measurement, X-ray imaging of tibia and/or femur; Device · Diagnostic Test
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 8 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Clinical trials in Orlando, Florida

Filter and sort this location

Live official records

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

Ultrasound Use to Measure Magnetically Controlled Growing Rods